Key result
Chronic amiodarone flattened restitution kinetics and was associated with lower sustained VT/VF induction compared to untreated patients with structural heart disease (18.2% vs 38.9%; P=0.07).
Why the study?
Does chronic amiodarone alter electrical restitution kinetics and reduce VT/VF induction in patients with structural heart disease?
Observational (n=52)
Does chronic amiodarone alter electrical restitution kinetics and reduce VT/VF induction in patients with structural heart disease?
Chronic amiodarone flattens electrical restitution kinetics in the human ventricle, which may explain its antiarrhythmic efficacy by limiting functional reentry.
Answers are grounded in this paper and cite their sources.
Amiodarone-associated restitution flattening may support antiarrhythmic effects; leaves open whether this reduces clinical VT/VF events.
INTRODUCTION: Dynamic instability of ventricular refractoriness represented by electrical restitution operates synergistically with tissue heterogeneity to increase the propensity for functional reentry leading to ventricular tachycardia/fibrillation (VT/VF). Little is known about the effect of chronic amiodarone on the electrical restitution in the human ventricle. METHODS AND RESULTS: Restitution kinetics of monophasic action potential duration (MAPD(90)) in the right ventricular outflow tract (RVOT) and apex (RVA), and of inverse of conduction time from RVOT to RVA (CT(-1)), were estimated by an S1-S2 protocol in 22 patients treated with amiodarone (180 ± 33 mg/day for 7 ± 9 months) and in 30 without treatment. In the untreated patients, the restitution kinetics of CT(-1) was steeper in the group with structural heart disease (SHD) (UNT(SHD+), n = 18) than without SHD (UNT(SHD-), n = 12), whereas MAPD(90) restitution parameters were comparable. In the amiodarone-treated patients (all with SHD), the shortest diastolic interval to produce a ventricular response (DI(min)) was increased, the maximum slope of MAPD(90) was flattened, and the magnitude of CT(-1) restitution was reduced as compared with UNT(SHD+). Sustained VT/VF was induced in 7 of 18 UNT(SHD+) (38.9%) and in 4 of 22 amiodarone-treated patients (18.2%, P = 0.07). Concomitant presence of increased CT(-1) restitution and dispersion of MAPD(90) restitution was required for the VT/VF induction. The suppression of VT/VF in the amiodarone-treated patients was associated with a smaller magnitude of CT(-1) restitution in the presence of limited dispersion of MAPD(90) restitution. CONCLUSION: Chronic amiodarone flattens restitution kinetics of MAPD(90) and CT(-1) in the human ventricle, which could be antiarrhythmic in patients with limited tissue heterogeneity.
No takes yet. Share an insight, caveat, or question.
Osaka et al. (2011) conducted an observational in Structural heart disease and risk of ventricular tachycardia/fibrillation (n=52). Chronic amiodarone vs. No treatment was evaluated on Induction of sustained VT/VF (p=0.07). Chronic amiodarone flattened restitution kinetics and was associated with lower sustained VT/VF induction compared to untreated patients with structural heart disease (18.2% vs 38.9%; P=0.07).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: